Clinical Implications of Hepatitis B Virus Variants  by Lin, Chih-Lin & Kao, Jia-Horng
J Formos Med Assoc | 2010 • Vol 109 • No 5 321
Contents lists available at ScienceDirect
Journal of the Formosan Medical Association
Journal homepage: http://www.jfma-online.com
J Formos Med Assoc 2010;109(5):321–325
Journal of the 
Formosan Medical Association
ISSN 0929 6646
Formosan Medical Association
Taipei, Taiwan
Volume 109 Number 5 May 2010
Clinical implications of HBV variants
GRP78 protein as a biomarker of oral cancer in Taiwan
Pemetrexed in heavily pretreated patients with advanced NSCLC
Sex differences in geriatric depression
News and Perspectives
Clinical Implications of Hepatitis B Virus Variants
Chih-Lin Lin,1,2 Jia-Horng Kao3,4,5,6*
Hepatitis B virus (HBV) is a global public health
problem and the leading cause of chronic hepati-
tis, cirrhosis, and hepatocellular carcinoma (HCC)
worldwide.1 As the smallest human DNA virus
with a genome of 3200 bp,2,3 the partially double-
stranded circular HBV DNA encodes four over-
lapping open reading frames: S gene for the surface
or envelope protein, C gene for the core protein,
P gene for the DNA polymerase, and X gene for
multifunctional nonstructural protein.4,5 The S
and C genes also have upstream regions desig-
nated pre-S and pre-C. The pre-S region contains
pre-S1 and pre-S2 domains (Figure 1).6 During
HBV DNA replication, DNA polymerase provides
reverse transcription at the intermediate stage. As
a result of the lack of proofreading function of
viral reverse transcriptase, HBV genome evolves
with an estimated rate of nucleotide substitution
at 1.4–3.2 × 10−5 per sites a year.7 This unique
replication strategy accounts for the majority of
point mutations and deletions or insertions ob-
served in the HBV genome. The long-term evolu-
tion of HBV therefore leads to the occurrence of
various genotypes, subgenotypes, mutants, recom-
binants, and even quasispecies.5,8
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Figure 1. The partially double-stranded circular DNA of
hepatitis B virus encodes four overlapping open reading
frames: Naturally occurring mutant strains including muta-
tions in precore and core promoter and deletion mutation
in pre-S genes are associated with the pathogenesis of
progressive liver disease. Adapted and modified from
Kao.6
On the basis of divergence in the entire HBV
genomic sequence of greater than 8%, at least eight
HBV genotypes (A–H) with distinct geographical
and ethnic distribution have been identified.9 The
influence of HBV genotype on disease progres-
sion and clinical outcomes has been increasingly
recognized. For example, patients with genotype
C or D infection are significantly more likely to
develop HCC than those with genotype A or B
infection.8,9 In addition, naturally occurring vari-
ations in the HBV genome also have implications
at the clinical and epidemiological levels. Several
HBV mutants, including precore/core promoter
mutations and pre-S/S deletion mutations, have
been reported to be associated with progressive
liver disease (Figure 1).10 In this article, the latest
advances in our understanding of the effect of
HBV variants on long-term clinical outcomes are
discussed.
Hepatitis B Precore/Core Promoter
Mutants
Hepatitis B e antigen (HBeAg) is a circulating pep-
tide that usually serves as a marker of active viral
replication.11 During the natural course of chronic
HBV infection, patients with HBeAg serocon-
version are usually in the low replication phase
or inactive carrier state, with low or undetectable
serum HBV DNA level (< 2000 IU/mL) and nor-
mal serum alanine aminotransferase level. How-
ever, a significant proportion of patients continue
to have a moderate level of HBV replication
(> 2000 IU/mL) and active liver disease that is des-
ignated as HBeAg-negative chronic hepatitis B.12
The clinical spectrum of HBeAg-negative chronic
HBV infection ranges from inactive carrier to 
aggressive chronic hepatitis with or without cir-
rhosis.13,14 Several HBeAg-negative viral mutant
strains are known to be responsible for the con-
tinuous HBV DNA replication after HBeAg 
seroconversion.15 HBV precore nucleotide 1896
mutation from G to A (precore G1896A) as well
as changes of two nucleotides, A to T transver-
sion at nucleotide 1762, together with a G to A
transition at nucleotide 1764 within the basal core
promoter (BCP A1762T/G1764A), lead to active
HBV replication in the absence of HBeAg.5,16–18
Several cohort and case-control studies have sug-
gested the controversial association between 
precore G1896A mutation and HCC develop-
ment.19–23 A recent meta-analysis has shown that
precore G1896A mutation is not significantly 
associated with HCC risk [odds ratio (OR) =
1.15, 95% confidence interval (CI)=0.83–1.60).24
Therefore, the appearance of precore G1896A
mutation alone might be an innocent bystander
and play a minimal role in the pathogenesis of
chronic HBV infection. However, BCP A1762T/
G1764A mutations have consistently been shown
to be associated with an increased risk of liver
disease progression and HCC development for
genotypes B and C infection.19–23 In a cohort
study, we have investigated the prevalence of BCP
A1762T/G1764A mutations in 250 genotype B- or
C-infected HBV carriers with different stages of
liver disease. The results have shown that geno-
type C has a higher prevalence of BCP A1762T/
G1764A mutations than genotype B (OR = 5.18,
95% CI = 2.59–10.37; p < 0.001). Patients with
BCP A1762T/G1764A mutations are signifi-
cantly more associated with the development of
HCC than those without (OR = 10.6, 95% CI =
4.92–22.86; p < 0.001).19 These findings have
been confirmed in a long-term follow-up study
of 1526 HBV carriers, which has shown the pres-
ence of BCP A1762T/G1764A mutations is an 
independent predictor for progression to HCC
(OR = 1.73, 95% CI = 1.13–2.67; p = 0.013).25 In
addition, a meta-analysis has yielded a summary
OR of 3.79 (95% CI = 2.71–5.29) for development
of HCC in patients with BCP A1762T/G1764A
mutations.24 Taking these lines of evidence to-
gether, BCP A1762T/G1764A mutation plays an
important role in liver disease progression in HBV
carriers, regardless of HBV genotype.
Mutations in enhancer II (C1653T) and else-
where in the BCP (T1753V) are associated with
HCC development. A case-control study from
Hong Kong has revealed that patients with
C1653T mutation have a significantly higher risk
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of HCC than those without (OR = 2.43, 95%
CI = 1.08–5.54; p = 0.028).26 Another cohort study
from Taiwan has indicated that patients with
T1753V mutation have a significantly higher risk
of HCC than those without (OR = 2.43, 95%
CI = 1.33–4.44; p = 0.028).27
Pre-S Gene Deletion Mutations
Deletion mutations in the pre-S gene of the HBV
genome frequently occur in chronic HBV infec-
tion.28,29 Deletion of the pre-S gene might affect
the expression of middle and small surface pro-
teins, which results in intracellular accumulation
of a large surface protein,30 and might contribute
to progressive liver cell damage and hepatocar-
cinogenesis.31,32 In our case-control study, the
frequency of pre-S deletion mutations was sig-
nificantly higher in genotype C than genotype B 
patients (33.8% vs. 11.6%, p = 0.01). The presence
of pre-S deletion mutations is an independent
risk factor associated with hepatitis activity (OR =
3.91, 95% CI = 1.57–9.76; p = 0.003) as well as
with development of HCC (OR = 3.72, 95% CI =
1.44–9.65; p = 0.007).33,34 Similarly, a longitudi-
nal study from Southern Taiwan has also shown
that pre-S deletion mutations are significantly 
associated with the development of liver cirrho-
sis and HCC over time.35 In addition, a matched
nested case-control study from China has shown
that pre-S deletion mutations constitute an inde-
pendent risk factor for HCC, and their emergence
and effect on HCC are independent of BCP mu-
tations.36 A meta-analysis has indicated that the
OR of HCC for pre-S deletion mutations was 3.77
(95% CI = 2.57–5.52).24 Our previous mapping
study of the pre-S region has suggested that all the
deletion regions encompass T- and B-cell epitopes,
and most of them lose one or more functional
sites, including those for polymerized human
serum albumin and nucleocapsid binding. There-
fore, HBV pre-S deletion mutations could lead to
defective immunity against HBV and contribute
to more progressive liver cell damage and finally
hepatocarcinogenesis.23
Complex Viral Mutations
HBV mutations in precore, core promoter and
pre-S genes accumulate during the course of
chronic HBV infection; therefore, the emergence
of complex HBV mutants is anticipated. In a cross-
sectional study to investigate the interactions
among precore G1896A mutation, BCP A1762T/
G1764A mutations and pre-S deletion mutations
in chronic hepatitis B patients with various stages
of liver disease,23 we found that a combination
of pre-S deletion and BCP A1762T/G1764A mu-
tations rather than single mutations is associated
with the development of progressive liver disease.
These results have been confirmed by a longitu-
dinal study, which has shown that two or three
combinations of pre-S deletion and BCP A1762T/
G1764A and C1766T and/or T1768A mutations,
rather than a single mutation are significantly 
associated with cirrhosis.35 In Hong Kong, Yuen
et al also reported that patients with BCP A1762T/
G1764A mutations and C1653T mutation have a
9.9-fold increased risk of HCC compared to pa-
tients with wild-type sequences for both regions.26
These findings suggest that accumulation of com-
plex viral mutations in the core promoter and
pre-S region synergistically affect the long-term
outcomes of HBV carriers.
The pattern of complex viral mutations is not
only an important risk factor associated with cir-
rhosis and HCC, but also a potential biomarker
for the prediction of HCC development. In a
meta-analysis of 43 studies, Liu et al found that
three combinations of C1653T, T1753V and BCP
A1762T/G1764A mutations have a high speci-
ficity (93.9%; 95% CI = 90.5–97.2) for the pre-
diction of HCC.24
Conclusions and Perspective
On the basis of existing lines of evidence, several
hepatitis B viral factors predictive of clinical out-
comes have been identified, including high HBV vi-
ral load, genotype C, and core promoter and pre-S
deletion mutations. Among these, persistently
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high serum HBV DNA level is the best predictor
of adverse outcomes (cirrhosis, HCC and death
from liver disease) in adult HBV carriers.6,10 In
addition, mutations in core promoter and pre-S
regions are also associated with an increased risk
of HCC (Figure 2).24 Thus these mutations might
serve as potential viral genetic markers to predict
disease progression, as well as help clinicians
identify patients who most need antiviral treat-
ment. However, molecular mechanisms involved
in the pathogenesis of these complex HBV muta-
tions remain largely unknown, and further stud-
ies are required to address this important issue.
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